GSK-872
GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury[1][2][3].
Product Specifications
CAS Number
[1346546-69-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
RIP kinase
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/GSK_acute_872.html
Purity
99.96
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C2N=CC=C(C2=C1)NC3=CC=C4SC=NC4=C3)(C(C)C)=O
Molecular Formula
C19H17N3O2S2
Molecular Weight
383.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56 (4) :481-95.|[2]Arora D, et al. Deltamethrin induced RIPK3-mediated caspase-independent non-apoptotic cell death in rat primary hepatocytes. Biochem Biophys Res Commun. 2016 Oct 14;479 (2) :217-223.|[3]Chen T, et al. Inhibiting of RIPK3 attenuates early brain injury following subarachnoid hemorrhage: Possibly through alleviating necroptosis. Biomed Pharmacother. 2018;107:563-570.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK3
Citation 01
ACS Appl Mater Interfaces. 2025 Aug 6;17 (31) :44803-44815.|ACS Infect Dis. 2025 Aug 19.|Acta Pharmacol Sin. 2022 May;43 (5) :1324-1336.|Adv Sci (Weinh) . 2024 Jun;11 (21) :e2309002.|Am J Cancer Res. 2021 May 15;11 (5) :2062-2080.|Ann Rheum Dis. 2024 Mar 19:ard-2023-224491.|Biochem Biophys Res Commun. 2020 Jun 11;526 (4) :1028-1035.|Biochem Biophys Res Commun. 2023 Sep 17:673:51-58.|Biomed Pharmacother. 2020 Jun;126:110102.|bioRxiv. 2023 Apr 25.|bioRxiv. 2024 Apr 26:2024.04.21.590456.|bioRxiv. 2025 Sep 5.|BMC Gastroenterol. 2022 Mar 26;22 (1) :137.|Cancer Lett. 2023 Jun 28:564:216208.|Cell Death Differ. 2022 Aug;29 (8) :1486-1499.|Cell Death Differ. 2025 Mar;32 (3) :506-520.|Cell Death Dis. 2021 Mar 3;12 (3) :230.|Cell Death Dis. 2025 Aug 29;16 (1) :657.|Cell Death Dis. 2025 Oct 24;16 (1) :759.|Cell Death Dis. 2020 Feb 19;11 (2) :134.|Cell Death Discov. 2022 Feb 2;8 (1) :44.|Cell Death Discov. 2022 Feb 26;8 (1) :88.|Cell Death Discov. 2023 Jul 26;9 (1) :262.|Cell Death Discov. 2024 May 28;10 (1) :261.|Cell Mol Life Sci. 2022 Jun 4;79 (6) :340.|Cell Rep Med. 2025 Aug 12:102291.|Cell Res. 2023 Mar;33 (3) :201-214.|Cell Res. 2023 Nov;33 (11) :851-866.|Cell Signal. 2025 Jan 3:111583.|Chin J of Oncol Prev and Treat. 2018, 10 (2) : 105-109.|Clin Cancer Res. 2023 Feb 1;29 (3) :667-683.|CNS Neurosci Ther. 2024 Jan;30 (1) :e14397.|EMBO Mol Med. 2025 Apr;17 (4) :679-695.|EMBO Rep. 2023 Nov 6;24 (11) :e56865.|Eur J Immunol. 2020 Jun;50 (6) :795-808.|Exp Eye Res. 2025 Aug 22:260:110581.|Exp Neurol. 2020 Sep;331:113374.|FASEB J. 2022 Dec;36 (12) :e22625.|Free Radic Biol Med. 2024 Aug 1:220:154-165.|Free Radic Biol Med. 2025 Jan:226:129-142.|Front Cell Infect Microbiol. 2022 Feb 4;12:825824.|Front Physiol. 2019 Jan 15;9:1922.|Immunol Cell Biol. 2021 Jan;99 (1) :34-48.|Int Immunopharmacol. 2022 Nov:112:109262.|Int Immunopharmacol. 2025 Sep 3:165:115427.|Int J Mol Sci. 2022 Sep 5;23 (17) :10170.|Invest New Drugs. 2020 Feb;38 (1) :50-59|iScience. 2021 Sep 25;24 (10) :103170.|J Dairy Sci. 2025 Aug;108 (8) :8844-8858.|J Immunol. 2018 Apr 15;200 (8) :2826-2834.|J Med Chem. 2019 May 9;62 (9) :4772-4778.|J Neurochem. 2025 Oct;169 (10) :e70246.|J Stroke Cerebrovasc Dis. 2022 Jan;31 (1) :106213.|J Virol. 2022 Jul 13;96 (13) :e0016722.|Korean J Physiol Pharmacol. 2023 May 1;27 (3) :231-240.|Life Sci. 2021 Nov 15:285:119963.|MedComm (2020) . 2025 Feb 18;6 (3) :e70107.|Microbiome. 2025 Apr 2;13 (1) :90.|Mol Immunol. 2023 Jan:153:160-169.|Mol Immunol. 2025 Jan 30:178:107-116.|Molecules. 2020 Mar 9;25 (5) :1225.|Nat Cell Biol. 2022 Apr;24 (4) :471-482.|Nat Commun. 2024 Jul 18;15 (1) :6043.|Nat Commun. 2025 Aug 7;16 (1) :7309.|Nat Commun. 2025 May 8;16 (1) :4288.|Nature. 2020 Apr;580 (7803) :386-390. |Naunyn Schmiedebergs Arch Pharmacol. 2025 Nov 26.|OncoTargets and Therapy Dovepress. 2020 May 18;15:1093-1101.|Phytomedicine. 2025 May 10:143:156840.|PLoS One. 2022 Oct 12;17 (10) :e0274116.|PLoS Pathog. 2025 May 13;21 (5) :e1013167.|Proc Natl Acad Sci U S A. 2025 Sep 23;122 (38) :e2507028122.|Res Sq. 2024 Jul 09.|Res Sq. 2024 May 13.|Research Square Preprint. 2023 Oct 3.|Research Square Print. 2022 May.|Research Square Print. January 4th, 2023.|Sci Rep. 2025 Apr 18;15 (1) :13377.|Sci Total Environ. 2024 Aug 30:175922.|Sci Total Environ. 2025 Mar 10:968:178852.|Signal Transduct Target Ther. 2020 Oct 9;5 (1) :235.|SSRN. 26 Oct 2022.|Stem Cells Int. 2024 Mar 14:2024:1348269.|Stroke. 2018 Oct;49 (10) :2473-2482.|Toxicology. 2025 Apr 4:154132.|Transl Stroke Res. 2021 Dec;12 (6) :991-1017.|Acta Pharm Sin B. 2023 Oct;13 (10) :4253-4272.|bioRxiv. 2024 Feb 21.|Research Square Print. September 23rd, 2022.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
040849-PE 200 µL
RASD2, ID (RASD2, TEM2, GTP-binding protein Rhes, Ras homolog enriched in striatum, Tumor endothelial marker 2) (PE) discontinued
Ask
View Details 
